U.S. Markets closed


NYSE . Currency in USD
Add to watchlist
Full screen
Previous CloseN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
Avg. VolumeN/A
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Market Realist3 months ago

    Johnson & Johnson’s Medical Devices Segment

    Johnson & Johnson’s (JNJ) Medical Devices segment revenues decreased ~0.1% to ~$25.1 billion for 2016, compared to 2015.

  • PR Newswire6 months ago

    Zimmer Biomet Strengthens Spine Offering with PrimaGen Advanced™ Allograft

    WARSAW, Ind., Dec. 13, 2016 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the launch of PrimaGen Advanced Allograft, an autograft substitute containing the same bone healing elements as autograft, but without the risks associated with donor site morbidity or harvest site complications.  Allograft is human tissue transplanted from a donor to a patient, while autograft tissue is transferred from one part of a patient's body to another.  PrimaGen Advanced Allograft offers a combination of demineralized cortical bone fibers with verified osteoinductivity and cancellous bone, providing a trabecular structure for natural bony in-growth with optimal handling and delivery characteristics. Dr. Donald Kucharzyk*, Orthopaedic Surgeon at The Orthopaedic, Pediatric and Spine Institute in Crown Point, Ind., was one of the first surgeons to use PrimaGen Advanced Allograft.  "The syringe allows for easy preparation and replication of the graft consistency prior to each use," noted Dr. Kucharzyk, who was pleased with the new delivery system, as well as the handling, moldability and stability under irrigation.

  • Market Realist6 months ago

    Johnson & Johnson’s Medical Devices Segment in 3Q16

    Johnson & Johnson’s (JNJ) Medical Devices segment grew ~1.1% to ~$6.2 billion for 3Q16 compared to 3Q15.